Scholar Rock (SRRK) Competitors

Scholar Rock (NASDAQ:SRRK) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Do institutionals and insiders believe in SRRK or GMAB?

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Which has more risk & volatility, SRRK or GMAB?

Scholar Rock has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Do analysts rate SRRK or GMAB?

Scholar Rock presently has a consensus target price of $42.67, suggesting a potential upside of 20.26%. Genmab A/S has a consensus target price of $37.60, suggesting a potential upside of 83.24%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67

Does the media favor SRRK or GMAB?

In the previous week, Genmab A/S had 2 more articles in the media than Scholar Rock. MarketBeat recorded 3 mentions for Genmab A/S and 1 mentions for Scholar Rock. Genmab A/S's average media sentiment score of 0.58 beat Scholar Rock's score of 0.00 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better earnings & valuation, SRRK or GMAB?

Genmab A/S has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	$33.19M	101.50	-$246.29M	-$2.53	-14.02
Genmab A/S	$3.12B	4.21	$1.14B	$1.76	11.66

Is SRRK or GMAB more profitable?

Genmab A/S has a net margin of 35.11% compared to Scholar Rock's net margin of 0.00%. Genmab A/S's return on equity of 18.08% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-118.22%	-82.01%
Genmab A/S	35.11%	18.08%	14.52%

Summary

Genmab A/S beats Scholar Rock on 12 of the 16 factors compared between the two stocks.